vTv Therapeutics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

vTv Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-113.5%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-113.5%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Aug 17

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Mar 03

vTv Therapeutics inks licensing deal for HPP971, shares up 11%

Dec 15

MacAndrews & Forbes buys 625K shares of vTv Therapeutics

Dec 11

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di VTVT siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di VTVT siano aumentati.

Rendimento dei dividendi rispetto al mercato

vTv Therapeutics Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di VTVT rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (VTVT)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Biotechs)	2.3%
Analista previsionale (VTVT) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di VTVT rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di VTVT rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di VTVT per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché VTVT non ha segnalato alcun pagamento.

vTv Therapeutics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

New major risk - Share price stability

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

New minor risk - Shareholder dilution

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

vTv Therapeutics Inc., Annual General Meeting, Jun 11, 2024

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

New minor risk - Shareholder dilution

Less than half of directors are independent

vTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Board Changes

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4.923802 million.

Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors

vTv Therapeutics Receives Non-Compliance Notice From Nasdaq

Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer

New minor risk - Share price stability

New major risk - Negative shareholders equity

First half 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1H 2022)

Nasdaq Approves vTv Therapeutics' Request to Extend the Period to Regain Compliance with the Minimum Bid Requirement Until December 18, 2023

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.10 loss in 1Q 2022)

vTv Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations

vTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel

vTv Therapeutics Receives a Letter from NASDAQ Regarding Minimum Bid Price

vTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer

Independent Director recently bought US$51k worth of stock

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021)

High number of new directors

Consensus revenue estimates increase by 17%

vTv Therapeutics Inc. Appoints Jonathan Isaacsohn as Member and Chair of the Board

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.01 loss in 2Q 2021)

vTv Therapeutics GAAP EPS of -$0.04

High number of new directors

vTv Therapeutics Inc. Announces CEO Changes

Jon Isaacsohn to Join the vTv Therapeutics Inc. Board of Directors

vTv stock soars 18% on $10M equity investment by CinRx Pharma

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics Inc. announced that it expects to receive $24.999762 million in funding from G42 Investments Ai Holding Rsc Ltd

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.075 loss in 1Q 2021)

vTv Therapeutics Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$5.00

Robin E. Abrams Resigns as Executive Chairperson of the Board of Directors of vTv Therapeutics Inc

vTv Therapeutics Inc. Announces Not to Stand for Re-Election of Noel Spiegel as Director and Chair of the Audit Committee of the Board

Price target decreased to US$5.00

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Inc. Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

vTv Therapeutics Inc.(NasdaqCM:VTVT) dropped from Russell 3000E Index

First quarter 2021 earnings released: US$0.075 loss per share (vs US$0.11 loss in 1Q 2020)

vTv Therapeutics Inc. Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

Director recently bought US$172k worth of stock

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Full year 2020 earnings released: US$0.18 loss per share (vs US$0.59 loss in FY 2019)

Revenue beats expectations

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

vTv Therapeutics inks licensing deal for HPP971, shares up 11%

MacAndrews & Forbes buys 625K shares of vTv Therapeutics

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti